Expert Interview
Diving into Emerging siRNA Therapies for Neuromuscular Diseases, Including Early Clinical Insights from Sarepta’s Pipeline for FSHD (SRP-1001) and DM1 (SRP-1003)
Ticker(s): SRPT, RNA, DYNInstitution: Ludwig-Maximilians-Universität München (LMU Klinikum)
Professor and Specialist in Neurology and Nutritional Medicine at the Friedrich-Baur-Institut, Neurological Clinic and Polyclinic, LMU Klinikum, focusing on neuromuscular diseases.
Manages 50 limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) patients
Serves as a key leader in clinical care and education, mentoring neurology residents and coordinating multidisciplinary teams for rare neuromuscular disorders. Leads research on therapeutic strategies for neuromuscular conditions, with over 100 publications advancing patient management in neurology.
How are neuromuscular diseases currently treated, and where are the biggest gaps in care today?
Added By: dami_adminWhat stands out to you about siRNA therapies compared to other treatment approaches?
What challenges or risks do you see for these treatments as they move through development?
What is your level of excitement for SRP-1003 and SRP-1001?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
